In patients with different forms of dementia we compared serum and cerebrospinal fluid concentrations of a-tocopherol (vitamin-E ), the major circulating lipid-soluble antioxidant, and neopterin, a product released from monocytic cells upon stimulation with interferon-y. A significant inverse correlation was found between the concentrations of both compounds in the cerebrospinal fluid. The data point to a role of oxidative stress to reduce antioxidant levels in elderly demented patients with neurodegenerative diseases.
Introduction
The etiology of neuronal death in neurodegenerative diseases remains unclear (l), most of which are characterized by a gradually progressing course. There is data indicating that excitotoxicity and oxidative damage could be involved in the pathogenesis of these diseases (2, 3) . Localized immw1e reaction and production of pro-inflammatory cytokines has been documented in the brain of patients with various neurodegenerative disorders, e.g., the synthesis of cytokines such as interleukin-6 was demonstrated immunohistochemically in plaques of Alzheimer's disease brains and confirms a cytokine-mediated process as part of the pathology (4). However, altered immune cell responsiveness and abnormal concentrations of in1mune mediators were not only described in neurodegenerative diseases but also in the healthy ~Corresponding author: Fritz Pregl Strasse 3, A-6020 llU1Sbruck, Austria. TeL +435125073519; fax: +43512 5072865 ; E-mail address:dietmaduchs @uibk.ac.at elderly (2, 5) . Activated phagocytic cells produce a variety of reactive oxygen species, and thus are an important source of oxidative stress during diseases. However, methods applicable for the assessment of oxidative stress in vivo are limited and suffer from low sensitivity. A strong association exists between the capacity of monocytes/ macrophages to release reactive oxygen species and the amount of neopterin upon stimulation with interferon-y (6, 7). Moreover, neopterin derivatives were described recently to be capable of enhancing effects of reactive oxygen species (8) . Thus, increased neopterin concentrations in body fluids of patients suffering from immunological disorders not only reflect immune activation but also can be regarded as an indicator of oxidative stress induced by reactive o)..),gen species released during the cellular in1mW1e response. Since neopterin is a stable product, the monitoring of neopterin concentrations is easily performed . As in patients with, e.g., virus infections, autoin1mune diseases or cancer, increased neopterin concentrations were also found in the semm of patients with Alzheimers disease and with Huntingtons disease, and an inverse correlation exis ted between Mini-Mental-State and neopterin concentrations (9, 10) . However, only a slight increase of neopterin concentrations h as been found in the CSF of these patients, and importantly, neopterin concentrations in CSF usually were lower than in paired serum or plasma specimens . This data imply that the increased concentrations of neopterin in the serum are not a result of overproduction of the compound inside the brain .
Lipid peroxidation by radical reactions is considered to contribute to tissue damage in neurodegenerative disorders. o:.-Tocopherol (vitamin-E) is a major lipid antioxidant which is capable of terminating free radical chai n reactions. During this reaction 0:.-tocopherol is oxidized, and concentrations of o:.-tocopherol were found decreased in the cerebrospinal fluid (CSF) and serum of patients with, e.g., Alzheimers disease (11) (12) (13) . Vice versa , treatment with seleginine and o:.-tocopherol ,,'as shown to slow the clinical deterioration of the disease (14, 15). Becau. 'ie o:.-tocopherol is a lipid-soluble yitamin that interacts with cell membranes, traps free radicals, and intermpts the chain reaction that damages cells. deficiency of o:.-tocopherol in the brain might be a consequence of increased oxidati\'e stress, and the efficacy of o:.-tocopherol in the treatment of patients could be due to its antioxidati\'e capacity. It is also noteworthy that patients suffering from familial inherited vitanun E (FIVE) deficiency develop almost identical neurological syndromes as observed 111 patients suffering from Friedreichs ataxia.
Patients and Methods
In this study \ve compared serum and CSF concentrations of o:.-tocopherol and neopterin in 10 patients with different forms of dementia (age: 70.8 ± 13.8 years; mean±S.D.) -5 patients w ith Alzheimers disease according to DSM-lIIR criteri a [16] (aged 72-85 years), 3 patients with vascular dementia (aged 77, 81, 85 years), and 2 patients with Huntingtons disease (aged 35 and 65 years) -and in 3 controls (57, 70, 77 = 68.0 ± 10.2 years). CSF and serum concentrations of o:.-tocopherol were measured by reversed phase high pressure liquid chromatography (HPLC) w ith fluorescence detection (290 nm excitation and 325 mn entission wavelength), and neopterin concentrations in serum and CSF were determined by ELISA (BRAHMS; Berlin, Germany) . In addition urinaty neopterin concentrations (flmol/mol creatinine) were measured by HPLC in early morning spot urine specimens (6) . D ata were analyzed by non-parametric Mann Whitney U -test, correlation analyses were done by Spearman rank: statistic'>. P-values below 0.05 were considered to indicate statistical significance.
Results
Semm concentrations of o:.-tocopherol were 23.7 ±3 .88 flM (mean±S.D.) and at the lower side compared to the 3 controls (27.2±4.59 flM; n .s.; Fig.   1 ), whereas serum neopterin concentrations (9.46 ±2 .97 n . . . \1 ) were higher than in controls (6.83± 2.39 nM; p=0.066). CSF o:.-tocopherol concentrations generally were 400-fold lower than semm levels, and again they were slighdy lower in patients 1.30 nM) totally overlapped with controls (6.27± 1.25; n.s.). Actually all of the patients with dementia had lower neopterin concentrations in CSF than in serum (U=2.9S, p=0.003; paired rank test). Patients had elevated urinary neopterin concentrations (mean±S.D.: 23S±S7 /-lmoljmol creatinine), and all but one patients had higher neopterin concentrations than the 3 controls (range: 132-177 /-lmoljmol creatinine). The one patient with Huntingtons disease was 35 years old and had a urinary neopterin concentration of 133 /-lmoljmol creatinine.
There existed an inverse correlation between CSF neopterin and a-tocopherol concentrations when specimens of all individuals were compared as well as when only patients with dementia were considered (Fig. 2) . In addition, a-tocopherol concentrations in CSF were significantly associated with their corresponding serum levels (rs=0.s99, p <0.05) and also urinary neopterin concentrations correlated with serum concentrations (rs =0.6s2, p <0.05). There was no correlation between age and neopterin or atocopherol concentrations, and there were no other significant relationships between the parameters investigated.
Discussion
Our data reveal no drastic increase of neopterin concentrations in patients with dementia compared to controls of similar age. However, the low number of controls does not allow a firm conclusion, but is obvious that with increasing age neopterin concentrations in healthy individuals are increasing (17) .
This is true for serum and CSF, and it is consistent with the view that neopterin concentrations as other indicators of immune system activation are increasing in body fluids with increasing age (2, 15) . From neopterin concentrations it appears that the relative increase with age is more pronounced in CSF than in serum (17) . Neopterin concentrations found in CSF of our patients not only fit well to the levels in healthy controls in this study but also to data available in the literature (17) . This result agrees well with recent observations on low or undetectable concentrations of neopterin, interferon-y and tumor necrosis factor-a in patients with Alzheimers disease (IS). In our study, we found a significant inverse correlation between neopterin and a-tocopherol concentrations in the CSF of patients suffering from different forms of dementia. Neopterin indicates immune activation and is indirectly and probably directly associated with oxidative stress. Thus, the inverse correlation found between neopterin and atocopherol in CSF is in line with the hypothesis that oxidative stress may be involved in the decrease of the antioxidant a-tocopherol and this could be part of the pathogenesis of these neurodegenerative disorders which cause dementia.
A positive correlation existed between a-tocopherol concentrations in serum and CSF. As serum concentrations of a-tocopherol are approximately 400-fold higher than that in CSF, it appears plausible that the decreased a-tocopherol concentrations in CSF might be a reflection of decreased a-tocopherol concentrations in the peripheral blood rather than oxidation of a-tocopherol within the blood brain barrier. The decreased availability of a-tocopherol in the CSF of older aged people may represent a cofactor for the development of dementia. This scenario is also in line with the fact that treatment with reductants like a-tocopherol or seleginine is of benefit for patients with neurodegenerative diseases (14, 15) . It is interesting to note that increased neopterin and decreased a-tocopherol levels were observed in all three groups of patients with dementia. Increased serum neopterin concentrations have also been described earlier in a patient with classic Creutzfeld-Jacob disease, again with lower concentrations in the CSF than in serum (19) , and the same situation appears to exist in patients with Parkinsons disease (20) . Yet, increased serum neopterin is not a general fmding in neurodegenerative disorders, rather it appears related to older age and to the development of dementia because patients with amyotrophic lateral sclerosis, who are usually much younger than patients with, e.g., Alzheimers disease, usually present with neopterin concentrations in serum and CSF within the normal range of healthy controls (21) . Also in our 35-years old patient with Huntingtons disease neopterin as well as a-tocopherol concentrations in the CSF are well within the normal range of the corresponding age group. Decreased concentrations of a-tocopherol have been described in serum of patients with Alzheimers disease already before (11) (12) (13) , but Iowa-tocopherol concentrations together with increased neopterin concentrations were also found in nonagenarians without dementia (22) .
Immune activation seems to increase in individuals witl1 older age, irrespective of the development of neurodegenerative disorders. In the same way, oxidative stress increases and contributes to a lower antioxidant capacity and lower a-tocopherol with increasing age which will support the development of neurodegenerative diseases in susceptible individuals. From our data it still remains unclear whether the d evelopment of neurodcgenerative disorders involves oxidati'-e stress greater than normal, which may further accelerate the loss of antioxidants like atocopherol.
Although correlation does not necessarilY indicate a cause-effect relationship, the finding of 100n:s r utocopherol in CSF of patients \\'ith higheq neopterin concentrations indicates that chronic immune activation and oxidati"e stress see m to contribute to depletion of u-tocopheroL ~u1Li decreased co ncentrations of the antioxidant in patients are unlikely to be just a result of reduced dietary intake.
